{"id":"NCT02582632","sponsor":"AbbVie","briefTitle":"A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults","officialTitle":"An Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Adults With Genotype 1b Hepatitis C Virus (HCV) Without Cirrhosis (GARNET)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-24","primaryCompletion":"2016-08-24","completion":"2016-12-01","firstPosted":"2015-10-21","resultsPosted":"2017-12-13","lastUpdate":"2021-07-30"},"enrollment":166,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Infection","Hepatitis C Virus"],"interventions":[{"type":"DRUG","name":"ombitasvir/paritaprevir/ritonavir","otherNames":["ABT-267/ABT-450/r","ombitasvir also known as ABT-267","paritaprevir also known as ABT-450"]},{"type":"DRUG","name":"dasabuvir","otherNames":["ABT-333"]}],"arms":[{"label":"Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety and efficacy of ombitasvir/paritaprevir/ ritonavir and dasabuvir administered for 8 weeks in treatment-naïve participants with genotype 1b (GT1b) hepatitis C virus (HCV).","primaryOutcome":{"measure":"Percentage of Participants Who Achieve Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","timeFrame":"12 weeks after the last actual dose of study drug","effectByArm":[{"arm":"Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir","deltaMin":97.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28416221"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":166},"commonTop":["HEADACHE","FATIGUE","NASOPHARYNGITIS","PRURITUS","NAUSEA"]}}